2.650EUR-6.36%Mkt Cap: 62.93M $P/E: —Today
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubato…
Industry Peers
Specialty Chemicals$221.79BUSDP/E 31.0
$115.62BUSDP/E 30.1
$115.51BUSDP/E 30.0
$84.22BUSDP/E 31.9
$78.91BUSDP/E 37.8
$67.52BUSD
$34.34BUSDP/E 31.7
$33.68BUSDP/E 28.4
$24.08BUSDP/E 63.3
$25.32BUSDP/E 16.3
$20.55BUSDP/E 38.6
$21.34BUSD
$21.27BUSD
$18.86BUSDP/E 59.9
$15.84BUSDP/E 497.0
$13.42BUSDP/E 50.8
$14.25BUSDP/E 21.6
$11.23BUSDP/E 16.2
$9.56BUSDP/E 24.2
$10.15BUSD
| Headline | Source | Time |
|---|---|---|
This week | ||
Older | ||
BBergsträsser Anzeiger | ||
EEcho Online | ||
CCHEManager | ||
 Earnings Release: Here's Why Analysts Cut Their BRAIN Biotech AG (ETR:BNN) Price Target To €5.24 BRAIN Biotech AG ( ETR:BNN ) just released its latest yearly report and things are not looking great. It definitely... | ||
BRAIN Biotech AG (ETR:BNN) Is Expected To Breakeven In The Near Future We feel now is a pretty good time to analyse BRAIN Biotech AG's ( ETR:BNN ) business as it appears the company may be... | ||
 BRAIN Biotech Third Quarter 2025 Earnings: €0.028 loss per share (vs €0.12 loss in 3Q 2024) BRAIN Biotech ( ETR:BNN ) Third Quarter 2025 Results Key Financial Results Revenue: €13.7m (up 1.6% from 3Q 2024). Net... | ||
The past five years for BRAIN Biotech (ETR:BNN) investors has not been profitable Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see... | ||